Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CEO James F. Oliviero III Sells 220,230 Shares

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CEO James F. Oliviero III sold 220,230 shares of Checkpoint Therapeutics stock in a transaction dated Thursday, December 19th. The shares were sold at an average price of $3.38, for a total transaction of $744,377.40. Following the completion of the transaction, the chief executive officer now directly owns 3,194,583 shares of the company’s stock, valued at approximately $10,797,690.54. This trade represents a 6.45 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Checkpoint Therapeutics Stock Performance

NASDAQ CKPT opened at $3.75 on Friday. The stock has a market cap of $183.12 million, a PE ratio of -2.04 and a beta of 1.34. The firm has a 50-day moving average of $3.59 and a 200-day moving average of $2.71. Checkpoint Therapeutics, Inc. has a 52-week low of $1.38 and a 52-week high of $4.50.

Checkpoint Therapeutics (NASDAQ:CKPT) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.08). As a group, analysts predict that Checkpoint Therapeutics, Inc. will post -0.91 EPS for the current fiscal year.

Institutional Trading of Checkpoint Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. Virtu Financial LLC acquired a new position in Checkpoint Therapeutics in the 3rd quarter valued at $30,000. XTX Topco Ltd acquired a new position in shares of Checkpoint Therapeutics in the second quarter valued at about $34,000. Gladstone Institutional Advisory LLC increased its position in Checkpoint Therapeutics by 141.4% during the third quarter. Gladstone Institutional Advisory LLC now owns 35,000 shares of the company’s stock worth $78,000 after acquiring an additional 20,500 shares during the period. Magnus Financial Group LLC raised its stake in Checkpoint Therapeutics by 12.9% in the 3rd quarter. Magnus Financial Group LLC now owns 35,000 shares of the company’s stock worth $78,000 after purchasing an additional 4,000 shares in the last quarter. Finally, Choreo LLC raised its stake in Checkpoint Therapeutics by 12.2% in the 2nd quarter. Choreo LLC now owns 65,002 shares of the company’s stock worth $133,000 after purchasing an additional 7,080 shares in the last quarter. 22.00% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

CKPT has been the subject of a number of research analyst reports. Lake Street Capital lifted their price target on Checkpoint Therapeutics from $4.00 to $7.00 and gave the stock a “buy” rating in a report on Monday, December 16th. HC Wainwright reiterated a “buy” rating and set a $20.00 target price on shares of Checkpoint Therapeutics in a research note on Monday, December 16th.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.